Publication number: 20220016243
Abstract: The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.
Type:
Application
Filed:
January 26, 2021
Publication date:
January 20, 2022
Applicants:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Catherine LAI, Janet LAU, Anthony Jongha LEE, Shi LI, Yvonne Gail LIN-LIU, Christina Jeanne MATHENY, Diana MENDUS, Raymond D. MENG, Anh NGUYEN DUC, Jilpa Bhupendra PATEL, Thinh Quang PHAM, Isabelle Anne ROONEY, Heather Blythe STEVENS, Sarah Marie TROUTMAN, Lijia WANG, Yulei WANG, Patrick Georges Robert WILLIAMS, Benjamin WU, Yibing YAN, Aijing ZHANG, Xiaosong ZHANG, Marcus Dale BALLINGER, Hila BARAK, Elizabeth Alexandra BENNETT, Marcela Lucia CASTRO, Edward Namserk CHA, Hui Min Phyllis CHAN, Stephen CHUI, Christopher Roland COTTER, Viraj Vinay DEGAONKAR, Barbara Jennifer GITLITZ, Tien HOANG, Kimberly Mayumi KOMATSUBARA